Source: Oculus Innovative Sciences, Inc.
Oculus Innovative Sciences, Inc.
(NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that
develops and markets solutions for the treatment of dermatological
conditions and advanced tissue care, today announced the commercial
launch into the U.S. dermatology market of the company’s newest
dermatology product, Lasercyn™. Under the supervision of a healthcare
professional, Lasercyn is intended for the management of
post-non-ablative laser therapy procedures, post-microdermabrasion
therapy and following superficial chemical peels. Lasercyn may also be
used to relieve itch and pain from minor skin irritations, lacerations,
abrasions and minor burns.
Dr. Michael Gold,
board-certified dermatologist and cosmetic surgeon, and founder of Gold
Skin Care Center, Advanced Aesthetics Medical Spa, The Laser &
Rejuvenation Center, and Tennessee Clinical Research Center, all located
in Nashville, Tennessee, commented, “Lasercyn is a promising new tool
for all aesthetic dermatologists who are looking to better manage
post-laser itch and pain associated with laser skin resurfacing, while
promoting enhanced healing and protection against secondary infections.
In our clinical testing of Lasercyn to date, we have seen dramatically
improved outcomes with quicker healing times and less patient discomfort
when Lasercyn is added to the post-procedure management protocol.”
For more information visit IntraDerm Pharmaceuticals at www.intraderm.com or phone 1-855-317-1107.
About Laser Skin Resurfacing
According to the Clinical, Cosmetic and Investigational Dermatology Journal,
medical and aesthetic skin procedures have seen a steady surge within
the last decade, and a higher demand for skin rejuvenation practices. In
2013 in the United States, dermatologic surgeons performed over 9.5
million treatments, an almost 22% increase from the previous year, with a
rising number of treatments involving skin resurfacing in the areas of
laser/light/energy-based procedures (2.25 million), chemical peels (1.1
million), and microdermabrasion (974,000).
Laser skin
resurfacing, also known as a laser peel, laser vaporization and
lasabrasion, can reduce facial wrinkles, scars and blemishes. Newer
laser technologies provide surgeons with a new level of control in laser
surfacing, permitting extreme precision, especially in delicate areas.
The laser beam used in laser resurfacing will remove outer layer of
skin, called the epidermis. It simultaneously heats the underlying skin,
called the dermis. This action works to stimulate growth of new
collagen fibers. As the treated area heals, the new skin that forms is
smoother and firmer. Common side effects include redness of the skin,
swelling of the treated area, itch, pain and moderate irritation similar
to the feeling produced by a mild sunburn.
About IntraDerm Pharmaceuticals
A
division of Oculus Innovative Sciences, IntraDerm Pharmaceuticals is a
global dermatology enterprise with an initial focus on Microcyn®
Technology and LipoGrid® technologies. The division’s headquarters are
in Petaluma, California with the international sales operations in the
Netherlands, and manufacturing operations in the United States and Latin
America. More information can be found at www.intraderm.com.
About Oculus Innovative Sciences, Inc.
Oculus
Innovative Sciences is a specialty pharmaceutical company that develops
and markets unique and effective solutions for the treatment of
dermatological conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring and
harmful inflammatory responses. The company's headquarters are in
Petaluma, California, with manufacturing operations in the United States
and Latin America. European marketing and sales are headquartered in
Roermond, Netherlands. More information can be found at www.oculusis.com.
No comments:
Post a Comment